• Kelloff G et al. Agents Biomarkers and cohorts for chemopreventive agent development in prostate cáncer. Urol 57(4A) 46-51, April 2001.
• Key T, Silcocks P, Davey G. A case-control study of diet and prostate cáncer. Br J Cáncer 76:678-687, 1997
• Key T, Thorogood M, Appleby P et al. Dietary habits and mortality in 11.000 vegetarians and health conscious people: results of a 17 year follow up. BMJ 313:775-779, 1996
• Key T, Fraser G, Thorogood M, et al. Mortality in vegetarians and non-vegetarians: a collaborative analysis of 8300 deaths among 76,000 men and women in five prospective studies. Public Health Nutr. 1(1):33-41, Mar 1998
• Keys A. Seven countries: a multivariate analysis of death and coronary heart disease. Cambridge, Máss Harvard Univ Press 1980
• Keys A. Coronary heart disease in seven countries. Circulation 1970;41 (suppl 1):1-211.
• Klein E, Thompson I. Update on chemoprevention of prostate cáncer. Curr Opin Urol. 14(3):143-149, May 2004
• Klein E. Selenium: Epidemiology and basíc science. J Urol 171 (2) part 2 of 2 : S50-S53, Feb 2004.
• Klein E. Clinical models for testing chemopreventive agents in prostate cáncer and overview of SELECT: The Selenium and Vitamin E Cáncer Prevention Trial. Recent Results Cáncer Res 163:212-225, 2003
• Klippel K, Hiltl D et al.A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol for the treatment of benign prostatic hyperplasía. German BPH-Phyto Study Group. Br J Urol 80:427-432, 1997
• Kirby R, Christmás T, Brawer M. Prostate Cáncer Epidemiological aspects Mosby 23-32, 1996
• Kirk P, Patterson R, Lampe J. Development of a soy food frecuency questionnaire to estimate isoflavone consumption in US adults. J Am Dietetic Ass 99(5),558-563, May 1999
• Knowles L, Zigrossi D, Tauber R, et al. Flavonoids suppress androgen-independent human prostate tumor proliferation. Nutr Cáncer 38(1):116-122, 2000
• Kogon M. Effects of medical and psychotherapeutic treatment on the survival of women with metastatic breast carcinoma. Cáncer 80(2):225-230,1997
• Kohnen P et al. Patterns of inflammation in prostatic hyperplasía: a histologic and bacteriologic study. J Urol. 121:755-760, 1979
• Kolonel L, Yoshizawa C, Hankin J. Diet and prostatic cáncer: a case-control study in Hawaii. American Journal of Epidemiology 127(5): 999-1012, 1988.
• Kolonel L, Hankin J, Whittemore A. Vegetables, fruits, legumes and prostate cáncer: a multiethnic case-control study. Cáncer Epidemiology, Biomarkers and Prevention 9(8): 795-804, 2000.
• Kolonel L, Nomura A et al. Dietary fat and prostate cáncer: current status. J Nat Cáncer Inst 91:414-428, 1999
• Kolonel L, Hankin J, Whittemore A et al.Vegetables, fruits, legumes and prostate cáncer: a multiethnic case-control study. Cáncer Epidemiology, Biomarkers and Prevention 9(8): 795-804, 2000
• Kondo Y et al. Promotional effect of two-generation exposure to a high-fat diet on prostate carcinogenesis in ACI/Seg rats. Cáncer Research 54(23): 6129-32, 1994.
• Konety B et al. Vitamin D in the prevention and treatment of prostate cáncer. Seminars in Urologic Oncology 17: 77-84, 1999
• Klein E, Thompson I, Lippman S et al. SELECT: The selenium and vitamin E cáncer prevention trial. Urol Oncol 21:59-65, 2003
• Klippel K, Hiltl D, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasía. German BPH-Phyto Study group. Br Journal Urology. 80:427–432, 1997
• Klotz L, Sies H. Defenses against peroxynitrite: selenocompounds and flavonoids Toxicology Letters 140-141:1:125–132, 2003
• Klotz L, Fleschner N, et al. A low-carbohydrate, high fat diet inhibits proliferation of prostate cáncer in vivo. Abstract # 579 Eur Urol Suppl 5(2):167, 2006
• Krzeski T, Kazón M, Borkowski A et al Combined extracts of Urtica dioica and Pygeum africanum in the treatment of benign prostatic hyperplasía: double-blind comparison of two doses.Clin Therapeutics 15(6):1011-1020, Nov-Dec 1993
• Krieger J et al.Chronic pelvic pains represent the most prominent urogenital symptoms of chronic prostatitis.Urol 48:715-22. 1996
• Krieger N. Epidemiology and the web of causation: has anyone seen the spider? Soc Sci. Med 39:887-903,1994
• Krishnan A, Moreno J, Nonn L et al. Novel pathways that contribute to the antiproliferative and chemopreventive activities of calcitriol in prostate cáncer. J Steroid Biochem Mol Biol. 103(3-5):694-702, March 2007
• Kristal A, Cohen J. Invited commentary: tomatoes, lycopene, and prostate cáncer. How strong is the evidence? American Journal of Epidemiology 151(2): 124-127, 2000.
• Kristal A. Vitamin A, retinoids and carotenoids as chemopreventive agents for prostate cáncer. J Urol 171(2):S54-S58, Feb 2004.
• Kristal A, Cohen J, Qu P, et al. Associations of energy, fat, calcium, and vitamin D with prostate cáncer risk. Cáncer Epidemiol
• Biomarkers Prev 11(8):719-725. Aug 2002
• Kucuk O, Sarkar F, Sakr W et al. Phase II Randomized Clinical Trial of Lycopene Supplementation before radical prostatectomy.
• Cáncer Epidemiol Biomarkers Prev 10:861-868,2001
• Kumar N et al.Nutrients in the chemoprevention of prostate cáncer.Current and Future Prospects. Canc Control 6(6):580-86, 1999 Kumar N, Cantor A, Allen K et al. The specific role of isoflavones in reducing prostate cáncer risk. Prostate 59: 141-147, 2004 Kumar R, Gupta N. Lycopene therapy in idiopathic male infertility: results of a clinical trial. Presented at: 34th Annual Conference
• of the Urological Society of India. Abstr # 102 January 18-21, 2001; Nagpur, India.
• Kupelian P, Klein E, Witte J. Familial prostate cáncer: a different disease? J Urol 158(6): 2197-2201, 1997.
• Kyprianou N, Isaacs J. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced
• programmed cell death. Molecular Endocrinology 3(10):1515-1522, 1989.
• Kyprianou N.Tahmatzopoulos A, Rowland RG. The role of alpha-blockers in the management of prostate cáncer. Expert Opin
• Pharmacother. 5(6):1279-1285, Jun 2004
• Kyprianou N, Chon JK, Partin AW et al. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis
• without affecting cell proliferation in patients with benign prostatic hyperplasía. J Urol 161(6):2002-2008, Jun 1999
• Kyprianou N, Zeng L. Apoptotic regulators in prostatic intraepithelial neoplasía (PIN): value in prostate cáncer detection and
• prevention. Prostate Cáncer Prostatic Dis. 8(1):7-13, 2005
• Kyprianou N, Zhu B.Transforming growth factor beta and prostate cáncer. Cáncer Treat Res. 126:157-173, 2005
• Kyprianou N, Chon J, Benning C. Effects of alpha(1)-adrenoceptor (alpha 1-AR) antagonists on cell proliferation and apoptosis in
• the prostate: therapeutic implications in prostatic disease. Prostate Suppl 9:42, 2000
• LaMartiniere C, Cotroneo M, Fritz W et al. Genistein chemoprevention: timing and mechanism, of action in murine mmamary and
• prostate. J Nutr 132:552S-558S, March 2002
• Lawson K, Wright M, Subar A, et al. Multivitamin use and risk of prostate cáncer in the National Institutes of Health-AARP Diet and
• Health Study. J Natl Cáncer Inst. 99(10):754-764, 16 May 2007
• Lazier C, Thomás L, et al. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in
• the LNCaP prostate cáncer cell line. Prostate. 58(2):130-144, 1 Feb 2004
• Le Marchand L, Hankin J, Kolonel L. Vegetable and fruit consumption in relation to prostate cáncer risk in Hawaii: a reevaluation
• of the effect of dietary beta-carotene. American Journal of Epidemiology 133(3): 215-219, 1991.
• La Vecchia C, Negri E, et al. Dairy products and the risk of prostatic cáncer. Oncology 48:406-410, 1991 Lee M, Wang R, Hsing A. Case control study of diet and prostate cáncer in China. Cáncer Causes Control 9(6):545-552,1998 Lee E et al. Thioallyl compounds: potent inhibitors of cell proliferation. Biochim Biophys Acta. 1221(1):73-77, 10 March 1994 Leitzmann M et al. Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cáncer. Am J Clin Nutr 80:204-216,2004 Leitzmann M, Stampfer M, Giovannucci E et al. Zinc supplement use and risk of prostate cáncer. JNCI 95: 1004-1007, 2003 Lekili M, et al. Zinc plasma levels in prostatic carcinoma and BPH. Interational Urology and Nephrology 23:151-154,1991. Lephart E et al. Neurobehavioral effects of dietary soy phytoestrogens . Neurotoxicology and Teratology, 24:1:5-16, 2002 Levy J, Bosin E, Feidman B et al. Lycopene is a more potent inhibitor of human cáncer cell proliferation than either alpha-carotene
• or beta-carotene. Nutrition & Cáncer 24:257-266,1995
• Levin R, Whitbeck C, Horan P et al. Low-dose tadenan protects the rabbit bladder from bilateral ischemia/ reperfusion-induced
• contractile dysfunction. Phytomedicine. 12(1-2):17-24, Jan 2005
• Lewis J, Adams D. Inflammation, oxidative DNA damage, and carcinogenesis. Env Health Persp 76:19-27,1987
• Lieberman R. Prostate cáncer chemoprevention: Strategies for designing efficient clinical trials. Urology 57:224-229, April 2001
• Lieberman R. Androgen deprivation therapy for prostate cáncer chemoprevention: current status and future directions for agent
• development. Urology Aug 58:83-90, 2001
• Lieberman R, Nelson W.New clinical trial strategies for prostate cáncer prevention.Urol 57(4A) Suppl April 2001
• Lieberman R et al. Progress in prostate cáncer chemoprevention: Modulators of promotion and progression Urol 58:835-842,2001
• Li H, Stampfer M, Hollis J et al. A Prospective Study of Plasma Vitamin D Metabolites, Vitamin D Receptor Polymorphisms, and
• Prostate Cáncer. PLoS Med. 20;4(3), Mar 2007
• Lin X et al. Effect of flaxseed supplementation on prostate carcinoma in transgenic mice Urology 60(5)919-924 Nov 2002
• Lim J, Piazza G, Han E, et al. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cáncer cell Lines
• Biochemical Pharmacology, 58:7:1097-1111, 1999